Orforglipron UK Availability: When Will the Weight-Loss Pill Launch?

Eli Lilly's oral GLP-1 pill orforglipron — brand name Foundayo™ — was approved by the US FDA on 1 April 2026, becoming the first once-daily weight-loss tablet of its kind on any market. UK patients are now asking the obvious question: when can we get it here?

This guide explains the current UK regulatory position, the expected MHRA and NICE timelines, when private and NHS access are realistic, what it's likely to cost, and how it's expected to fit alongside Mounjaro and Wegovy in Britain's fast-changing weight-loss landscape.

New to orforglipron? Start with our explainer on what orforglipron is. For the trial numbers behind the hype, see our breakdown of how well orforglipron works.

The short answer

US: Foundayo (orforglipron) was approved by the FDA on 1 April 2026 and is shipping to US patients via LillyDirect from 6 April 2026.
UK: Lilly is expected to submit Foundayo to the MHRA in mid-2026.
Private prescriptions in the UK: realistically available from late 2026 to 2027, once MHRA approval is granted.
NHS prescriptions: unlikely before 2027 at the earliest, and probably with restricted criteria, after NICE has completed its appraisal.

Nothing is guaranteed — regulators set their own pace, and supply once approved is another question entirely. But the direction of travel is clear.

What "approved" means — and what it doesn't

The April 2026 FDA decision applies to the United States only. UK approval is a separate process, run by the Medicines and Healthcare products Regulatory Agency (MHRA), who must independently assess Foundayo's safety, efficacy, and manufacturing quality before any UK prescription can be written for it.

In practice, that means the FDA's green light makes UK approval more likely and probably faster, but it doesn't automatically deliver it. Lilly has to file a separate dossier with the MHRA, the MHRA has to review it, and that takes months.

A drug being available legally in the UK is a two-step gate:

MHRA approval — required for any UK prescription (private or NHS).
NICE recommendation (in England) — required for routine NHS prescribing on the cost-effectiveness grounds the NHS uses. The Scottish Medicines Consortium and All Wales Medicines Strategy Group do equivalent work in Scotland and Wales.

You can be prescribed an MHRA-approved drug privately as soon as it's approved — that's the typical route during the gap between MHRA and NICE decisions. That's exactly what happened with Wegovy and Mounjaro.

The MHRA timeline for orforglipron

Based on Lilly's public guidance, the expected sequence is:

Mid-2026: MHRA submission filed
Late 2026 to early 2027: MHRA decision expected
Late 2026 onwards: First private UK prescriptions possible after approval
2027 onwards: NICE appraisal completed; potential NHS access (with criteria)

This isn't a guarantee — regulators set their own pace. But the FDA's early approval, combined with the fact that the safety profile mirrors the well-known injectable GLP-1s, makes a relatively fast UK review plausible.

Will orforglipron be on the NHS?

Eventually, probably yes — but with the same hurdles every new weight-loss medication has faced.

The NHS doesn't simply hand out new drugs as soon as they're approved. NICE assesses whether the drug delivers enough value for the price. Once recommended, the NHS still typically restricts access at first — often only through specialist weight-management services, with strict BMI and comorbidity criteria.

This is the pattern Mounjaro and Wegovy followed. NHS prescribing for orforglipron is not expected before 2027 at the earliest, even in the most optimistic scenario.

Three factors will probably drive how generous NHS access ultimately becomes:

Price. Oral small-molecule drugs are typically cheaper to manufacture at scale than injectable peptides. If Lilly prices Foundayo aggressively, NICE's cost-effectiveness calculation gets easier.
Supply. The injectable GLP-1s have repeatedly hit supply problems. Foundayo, as a standard tablet, should be much easier to manufacture and distribute — a real advantage for NHS rollout.
Long-term outcomes data. As ATTAIN-MAINTAIN and post-approval studies mature, the NHS case for funding long-term obesity treatment is likely to strengthen.

What about private prescriptions?

The faster route for most UK patients will be private prescription — exactly as it was for Mounjaro and Wegovy in their first year of UK availability.

Once the MHRA approves Foundayo, expect to see it offered through:

Online weight-loss clinics (the main route for current GLP-1 access in the UK)
Private GP practices with weight-management services
High street pharmacy chains with online doctor services

The price will not be set by the NHS — it will be set by Lilly and marked up by the prescriber. We track current pricing in our GLP-1 pricing guide.

What will orforglipron cost in the UK?

Lilly has not yet announced UK pricing for Foundayo. As a reference point, in the US the announced self-pay price starts at $149 (around £120) per month for the lowest dose, with discounts down to $25 per month for eligible commercially-insured patients.

UK pricing usually lands lower than US list prices, but the private prescription market in the UK adds a clinic/dispensing markup. A reasonable expectation, based on how Wegovy and Mounjaro launched here, is that monthly cost will likely sit somewhere between the price of branded oral diabetes drugs and the current price of weekly Mounjaro pens — though that's an educated guess, not a quote.

We'll update our pricing guide as soon as Lilly publishes a UK list price.

How will orforglipron fit alongside Mounjaro and Wegovy?

The UK weight-loss medication landscape in 2026 looks roughly like this:

Drug	Form	UK status (May 2026)	Brand
Semaglutide	Weekly injection	Approved; private + restricted NHS	Wegovy
Tirzepatide	Weekly injection	Approved; private + restricted NHS	Mounjaro
Orforglipron	Daily tablet	Not yet approved; FDA-approved in US	Foundayo
Oral semaglutide	Daily tablet (with timing rules)	Approved for type 2 diabetes only	Rybelsus

Orforglipron's appeal in the UK is straightforward: it's the only weight-loss drug in this class that's a flexible daily tablet. No injection. No fridge. No fasting rules around when you take it.

That doesn't mean it will displace the injectables overnight. In indirect comparisons:

Wegovy has produced larger average weight loss than orforglipron (~14.9% vs ~11.2%) at top doses.
Mounjaro has produced larger still (~20.9% at the top dose).
Orforglipron sits below both — but is genuinely easier to take, less variable in supply, and likely cheaper.

For many patients, especially those put off by needles or struggling to get reliable supply of injectables, that's an attractive trade-off.

Risks and unknowns

A few things are worth keeping a level head about:

Approval is not certain. Most drugs that complete Phase 3 do get approved, but the MHRA can ask for more data, request additional analyses, or impose restrictions that delay launch.
NHS access will be tight. Even when NICE recommends weight-loss medication, NHS rollout has been slow. Don't expect orforglipron to be widely available on the NHS in 2027 even if it's approved.
Counterfeits. Until Foundayo is properly available in the UK, any site claiming to sell it should be treated as unsafe and likely fraudulent. The MHRA actively warns about this for new high-demand drugs.
Long-term use. Like all GLP-1 medications, weight tends to return when the drug is stopped. Plan for the medication as part of a long-term approach, not a six-month fix.

FAQs

When will orforglipron be available in the UK?
Lilly is expected to file with the MHRA in mid-2026. Private prescriptions in the UK are most likely from late 2026 or 2027 once MHRA approval is granted. NHS access is not expected before 2027.

Will orforglipron be available on the NHS?
Eventually, yes — but only after MHRA approval and a NICE appraisal, and almost certainly with restricted prescribing criteria similar to those for Mounjaro and Wegovy.

What is Foundayo?
Foundayo is Eli Lilly's brand name for orforglipron, the once-daily oral GLP-1 weight-loss pill. The drug name and brand name refer to the same medication.

Can I buy orforglipron online now?
No. Until orforglipron / Foundayo is approved by the MHRA, it cannot legally be prescribed or sold in the UK. Any website offering it before then is highly likely to be selling either a fake or an illegally imported product — both are dangerous. The MHRA has repeatedly warned consumers about counterfeit GLP-1 medications.

How much will orforglipron cost in the UK?
Lilly has not yet set UK pricing. In the US it starts at $149/month self-pay (around £120) for the lowest dose, with discounts available. Private UK clinic pricing will include a markup. We'll publish UK prices in our pricing guide as soon as they're confirmed.

Will orforglipron replace Wegovy or Mounjaro?
Probably not for everyone. The injectables still produce larger average weight loss in trials. Orforglipron is likely to be the preferred option for patients who can't or won't inject, who prefer daily tablets, or who need a treatment with simpler storage and supply.

Will my UK private clinic switch me to orforglipron?
Possibly, once it's approved here. Most reputable clinics will discuss the trade-offs with you rather than automatically switching. Don't change your medication without speaking to your prescriber.

Is orforglipron approved anywhere else?
Yes — the FDA approved Foundayo in the US on 1 April 2026. Lilly has stated it will pursue regulatory submissions in other major markets, including the EU and UK, over the course of 2026.

This article reflects publicly known regulatory and market information as of May 2026. Regulatory timelines can change. This article is for general information only and does not constitute medical advice. Orforglipron / Foundayo is not currently licensed for use in the UK; do not attempt to obtain it through unregulated channels. Always speak to a qualified healthcare professional before starting, stopping, or considering any prescription medication.